Business
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
Lunai Bioworks' (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the LouLou Foundation.
About this update from Lunai Bioworks Inc.
[{"type":"text","content":"Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development","length":182,"tagName":"p"},{"type":"text","content":"SACRAMENTO, Calif. and SAN DIEGO, May 28, 2026 /PRNewswire/ -- Lunai Bioworks' (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the LouLou Foundation.","length":411,"tagName":"p"},{"type":"image","alt":"Announcing A Foundation-Funded Neurology Collaboration","displaySize":"","headline":null,"caption":"Announcing A Foundation-Funded Neurology Collaboration","className":"","disableSlideshowImg":false,"size":{"original":{"width":320,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/22870407f19daf7986a333374e6f4b1d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/btdUFzlDFKTB7x3RDE.eLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTgwMA--/https://media.zenfs.com/en/prnewswire.com/22870407f19daf7986a333374e6f4b1d","width":320,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/btdUFzlDFKTB7x3RDE.eLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTgwMA--/https://media.zenfs.com/en/prnewswire.com/22870407f19daf7986a333374e6f4b1d","width":320,"height":400}},"href":"https://mma.prnewswire.com/media/2989184/LUNAI_BIOWORKS_INC__Collaboration.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The collaboration combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm Therapeutics' proprietary human-derived organoid systems to create an integrated translational engine for neurology drug discovery. The companies intend to generate high-confidence therapeutic programs designed for pharmaceutical partnering, licensing, and downstream development.","length":414,"tagName":"p"},{"type":"text","content":"The collaboration is aligned with emerging FDA guidance encouraging adoption of innovative new approach methodologies (NAMs) that improve human translational relevance and reduce dependence on traditional mammalian animal models in drug development. Initial efforts will foc...